CDK9 and prostate cancer: We earlier performed a comprehensive screen to discover compounds that sensitize prostate cancer cells to OGT inhibitors, and this work led to the discovery of combinatorial lethal interaction between OGT and CDK9 inhibitors that is specific to prostate cancer cells [23].